Xylazine and Opioid Use: An Update

Videoconference via Zoom

August 14, 10:00am-11:30am (Eastern Time)

Description

The urgency of the opioid crisis that began in 2019 has not abated and fentanyl continues to fuel the overdose rates. More recently, an emerging trend has been identified. Yet another dangerous substance called Xylazine has been found more frequently in various illicit substances and is worsening outcomes for people who use opioids.

This webinar is intended to provide the latest information available on Xylazine, including associated effects on the body and long-term impacts on opioid users, and review current organizational strategies to help prevent exacerbated and related harm.

Trainer

Diana Padilla, MCPC, CARC, CASAC-T, is a Research Project Manager at New York State Psychiatric Institute, Columbia University Medical Center. She is a senior staff trainer for the Northeast & Caribbean Addiction Transfer Technology Center Network (NeC-ATTC), and a member of the ASAP-NYCB Trainer Registry. As a cultural agent, Ms. Padilla promotes an equity lens in trainings for engaging diverse communities in need, aligning with evidence and strength-based strategies within behavioral health, addiction, prevention, and recovery supports fields and professional capacities.

Credits

This training meets the requirements for 1.5 renewal hours (CASAC, CPP, CPS) and 1.5 initial hours (CPP, CPS) through New York State's Office of Addiction Services and Supports (NYS OASAS). As an IC & RC member board, OASAS accredited courses are granted reciprocal approval by the New Jersey Division of Consumer Affairs, Alcohol and Drug Counselor Committee. Many other states offer reciprocity - please check with your accrediting agency.

Participants are required to attend the session in its entirety, turn on their video cameras, and actively participate in order to receive credit.

CLICK HERE TO REGISTER

(Please register in advance)

Please contact Tri Chaple at patricia.chaple @nyspi.columbia.edu with any questions.